In This Article:
What Happened?
Shares of healthcare product and device company Abbott Laboratories (NYSE:ABT) jumped 5.4% in the morning session after the company reported decent first-quarter 2025 results with revenue in line, although its organic revenue fell slightly short of Wall Street's estimates. EPS in the quarter beat slightly, while full-year EPS guidance met expectations. The full-year sales outlook was also maintained, which was encouraging despite the uncertain macro backdrop.
Taking a closer look at the numbers, the company recorded a 12.6% organic growth in its Medical Devices segment, powered by robust demand for diabetes care and heart-related technologies. This strength helped lift total company organic sales by 6.9%, with double-digit growth in U.S. sales, even as Diagnostics weighed on results due to falling COVID-19 testing demand. Overall, this was a good quarter without many big surprises, which is a good thing in this market.
The shares closed the day at $129.72, up 2.8% from previous close.
Is now the time to buy Abbott Laboratories? Access our full analysis report here, it’s free.
What The Market Is Telling Us
Abbott Laboratories’s shares are not very volatile and have only had 1 move greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
Abbott Laboratories is up 14.3% since the beginning of the year, and at $129.70 per share, it is trading close to its 52-week high of $140.22 from March 2025. Investors who bought $1,000 worth of Abbott Laboratories’s shares 5 years ago would now be looking at an investment worth $1,351.
Today’s young investors likely haven’t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.